Fidest – Agenzia giornalistica/press agency

Quotidiano di informazione – Anno 31 n° 344

Poxel Appoints Takashi Kaneko, MD, PhD, as Senior Vice President Medical and President of Poxel Japan K.K.

Posted by fidest press agency su sabato, 15 settembre 2018

POXEL SA (Euronext – POXEL – FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), today announced that Takashi Kaneko, MD, PhD, has joined Poxel as Senior Vice President Medical and President of Poxel Japan K.K., effective September 1, 2018, to lead the Company’s drug development and medical affairs activities as well as the team in Japan. In addition, the Company has established a wholly-owned Japanese subsidiary in Tokyo.
“Japan has been a strategic focus for Poxel and we have made significant progress in the development of Imeglimin for the treatment of type 2 diabetes for this market. This includes a robust Phase 2b program, which resulted in the strategic partnership with Sumitomo Dainippon Pharma for Japan, China and eleven other Asian countries. We are also advancing the Imeglimin Phase 3 TIMES program in Japan, with our partner Sumitomo, for which we expect the first data results in the first half of 2019,” said Thomas Kuhn, CEO of Poxel. “The addition of Dr. Kaneko to our team with his medical affairs and clinical development expertise and knowledge of the Japanese market is of great importance to Poxel today and moving forward as we continue to expand our efforts in Japan through our newly established subsidiary in Tokyo.”
Dr. Kaneko brings to Poxel over 33 years of experience including pharmaceutical industry experience with a focus on medical affairs and clinical development ranging from product evaluation, development and post-commercial launch, and clinical practice and medical research experience. Dr. Kaneko joins Poxel from Janssen Pharmaceutical K.K., where he was Head of Medical Affairs. Prior to Janssen Pharmaceutical K.K., he was the Department Head of the Medical Excellence Department in the Medical Division at Novartis K.K. Dr. Kaneko also held several senior-level positions at Santen, which included the areas of Compliance, Global Clinical Development and Medical Affairs, Head of Global Research and Development as well as other research and development-related positions. In addition, Dr. Kaneko was a Vice President, Medical Director at Sanofi-Aventis K.K., and served in clinical development roles at Bristol-Myers K.K., BMS, Japan. Dr. Kaneko holds an MD and PhD degree from the University of Tokyo, Tokyo, Japan.

Rispondi

Inserisci i tuoi dati qui sotto o clicca su un'icona per effettuare l'accesso:

Logo di WordPress.com

Stai commentando usando il tuo account WordPress.com. Chiudi sessione /  Modifica )

Google photo

Stai commentando usando il tuo account Google. Chiudi sessione /  Modifica )

Foto Twitter

Stai commentando usando il tuo account Twitter. Chiudi sessione /  Modifica )

Foto di Facebook

Stai commentando usando il tuo account Facebook. Chiudi sessione /  Modifica )

Connessione a %s...

 
%d blogger hanno fatto clic su Mi Piace per questo: